Sphingomyelinase decreases transepithelial anion secretion in airway epithelial cells in part by inhibiting CFTR-mediated apical conductance.


Journal

Physiological reports
ISSN: 2051-817X
Titre abrégé: Physiol Rep
Pays: United States
ID NLM: 101607800

Informations de publication

Date de publication:
08 2021
Historique:
received: 19 05 2021
accepted: 21 05 2021
entrez: 12 8 2021
pubmed: 13 8 2021
medline: 1 3 2022
Statut: ppublish

Résumé

The cystic fibrosis transmembrane conductance regulator (CFTR) is an anion channel whose dysfunction causes cystic fibrosis (CF). The loss of CFTR function in pulmonary epithelial cells causes surface dehydration, mucus build-up, inflammation, and bacterial infections that lead to lung failure. Little has been done to evaluate the effects of lipid perturbation on CFTR activity, despite CFTR residing in the plasma membrane. This work focuses on the acute effects of sphingomyelinase (SMase), a bacterial virulence factor secreted by CF relevant airway bacteria which degrades sphingomyelin into ceramide and phosphocholine, on the electrical circuitry of pulmonary epithelial monolayers. We report that basolateral SMase decreases CFTR-mediated transepithelial anion secretion in both primary bronchial and tracheal epithelial cells from explant tissue, with current CFTR modulators unable to rescue this effect. Focusing on primary cells, we took a holistic ion homeostasis approach to determine a cause for reduced anion secretion following SMase treatment. Using impedance analysis, we determined that basolateral SMase inhibits apical and basolateral conductance in non-CF primary cells without affecting paracellular permeability. In CF primary airway cells, correction with clinically relevant CFTR modulators did not prevent SMase-mediated inhibition of CFTR currents. Furthermore, SMase was found to inhibit only apical conductance in these cells. Future work should determine the mechanism for SMase-mediated inhibition of CFTR currents, and further explore the clinical relevance of SMase and sphingolipid imbalances.

Identifiants

pubmed: 34382377
doi: 10.14814/phy2.14928
pmc: PMC8358481
doi:

Substances chimiques

Anions 0
CFTR protein, human 0
Cystic Fibrosis Transmembrane Conductance Regulator 126880-72-6
Sphingomyelin Phosphodiesterase EC 3.1.4.12

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14928

Subventions

Organisme : NHLBI NIH HHS
ID : F31 HL143863
Pays : United States
Organisme : NIGMS NIH HHS
ID : F31 GM130112
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA025854
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008602
Pays : United States

Informations de copyright

© 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

Références

N Engl J Med. 2018 Oct 25;379(17):1612-1620
pubmed: 30334692
FASEB J. 1996 Oct;10(12):1388-97
pubmed: 8903509
Nat Med. 2005 May;11(5):491-8
pubmed: 15852018
Science. 1989 Sep 8;245(4922):1059-65
pubmed: 2772657
Chromatographia. 2015;78(5-6):403-413
pubmed: 25750457
Cold Spring Harb Perspect Med. 2012 Jun;2(6):a009563
pubmed: 22675668
J Biol Chem. 2007 Dec 28;282(52):37402-11
pubmed: 17932048
Am J Respir Cell Mol Biol. 2001 Dec;25(6):676-84
pubmed: 11726392
J Clin Invest. 2002 Dec;110(11):1651-8
pubmed: 12464670
Nature. 2014 Jun 5;510(7503):58-67
pubmed: 24899305
Science. 1989 Sep 8;245(4922):1066-73
pubmed: 2475911
J Clin Invest. 1991 Oct;88(4):1422-31
pubmed: 1717515
Sci Rep. 2019 Sep 17;9(1):13460
pubmed: 31530897
Mol Microbiol. 2004 Aug;53(4):1089-98
pubmed: 15306013
J Gen Physiol. 2019 Jun 3;151(6):834-849
pubmed: 31048413
J Pharmacol Exp Ther. 2010 Apr;333(1):60-9
pubmed: 20051483
J Mol Med (Berl). 2017 Oct;95(10):1053-1064
pubmed: 28695226
Chem Biol Interact. 2019 Feb 1;299:168-178
pubmed: 30553721
Chem Biol. 2014 May 22;21(5):666-78
pubmed: 24726831
Lancet. 2016 Nov 19;388(10059):2519-2531
pubmed: 27140670
Pediatr Pulmonol. 2019 Nov;54 Suppl 3:S13-S17
pubmed: 31715091
Biophys J. 2004 Nov;87(5):3264-76
pubmed: 15315952
FEBS Lett. 2006 Aug 21;580(19):4751-6
pubmed: 16901483
Exp Cell Res. 2017 Jun 15;355(2):153-161
pubmed: 28390677
FEBS Lett. 2004 Feb 13;559(1-3):96-8
pubmed: 14960314
Am J Respir Cell Mol Biol. 2000 Apr;22(4):460-8
pubmed: 10745027
Sci Rep. 2017 Jun 7;7(1):2931
pubmed: 28592822
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3591-6
pubmed: 19208806
J Biol Chem. 2010 Nov 12;285(46):35706-18
pubmed: 20807762
J Bacteriol. 2007 Dec;189(23):8719-26
pubmed: 17873030
Biochem Biophys Res Commun. 2004 Nov 12;324(2):901-8
pubmed: 15474513
Methods Mol Med. 2002;70:129-42
pubmed: 11917518
Br J Pharmacol. 2014 Aug;171(15):3716-27
pubmed: 24758416
J Med Chem. 2008 Jan 24;51(2):219-37
pubmed: 18027916
Front Physiol. 2021 Feb 04;12:619442
pubmed: 33613309
Pediatr Pulmonol. 2017 Nov;52(S48):S4-S14
pubmed: 28881097
Glycoconj J. 2020 Oct;37(5):623-633
pubmed: 32666337
Mol Aspects Med. 2018 Oct;63:59-69
pubmed: 30098327
Nat Commun. 2016 Jul 25;7:12276
pubmed: 27452368
Am J Physiol Renal Physiol. 2007 Oct;293(4):F1178-86
pubmed: 17634398
J Biol Chem. 2006 Aug 25;281(34):24695-703
pubmed: 16803890
J Physiol. 1990 Aug;427:567-81
pubmed: 2120430
JOP. 2001 Jul;2(4 Suppl):219-28
pubmed: 11875263
Subcell Biochem. 2010;51:509-49
pubmed: 20213557
Methods Mol Biol. 2011;741:39-54
pubmed: 21594777
Biol Chem. 2015 Jun;396(6-7):707-36
pubmed: 25803076
Am J Respir Crit Care Med. 2020 Oct 15;202(8):1133-1145
pubmed: 32569477
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8
pubmed: 21976485
Methods. 2006 Jun;39(2):82-91
pubmed: 16828308
Environ Sci Technol. 2014 Feb 18;48(4):2097-8
pubmed: 24476540
Methods Mol Med. 2005;107:183-206
pubmed: 15492373
Am J Respir Cell Mol Biol. 2008 Jan;38(1):47-56
pubmed: 17656682
Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L894-902
pubmed: 15626749
Biophys J. 2000 Jul;79(1):314-20
pubmed: 10866957

Auteurs

Kirsten A Cottrill (KA)

Molecular and Systems Pharmacology PhD Program, Emory University, Atlanta, Georgia, USA.

Raven J Peterson (RJ)

Biochemistry, Cell, and Developmental Biology PhD Program, Emory University, Atlanta, Georgia, USA.

Colby F Lewallen (CF)

Georgia Institute of Technology, G.W. Woodruff School of Mechanical Engineering, Atlanta, Georgia, USA.

Michael Koval (M)

Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University, Atlanta, Georgia, USA.
Department of Cell Biology, Emory University, Atlanta, Georgia, USA.

Robert J Bridges (RJ)

Department of Physiology and Biophysics, Center for Genetic Diseases, Chicago Medical School, North Chicago, Illinois, USA.

Nael A McCarty (NA)

Molecular and Systems Pharmacology PhD Program, Emory University, Atlanta, Georgia, USA.
Department of Pediatrics and Children's Healthcare of Atlanta, Center for Cystic Fibrosis and Airways Disease Research, Emory University School of Medicine, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH